Richard Angell

USPTO Granted Patents = 13 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 6.1

ph-index = 8

Forward Citations = 104(Granted Patents)

Company Filing History:

Smithkline Beecham Corporation

Years Active: 2006-2023

Loading Chart...

13 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11560380 - Substituted naphthalene diimides and their use (2023-01-24),

2. 9809575 - Pharmaceutical compounds (2017-11-07),

3. 8008303 - Biphenyl derivatives and their use in treating hepatitis C (2011-08-30),

4. 7642276 - Fused heteroaryl derivatives for use as P38 kinase inhibitors (2010-01-05),

5. 7432289 - 5-Acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors (2008-10-07),

6. 7425555 - Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors (2008-09-16),

7. 7396843 - 5'-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors (2008-07-08),

8. 7384963 - 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase (2008-06-10),

9. 7309800 - Biphenylcarboxylic amide derivatives as p38 kinase inhibitors (2007-12-18),

10. 7208629 - 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors (2007-04-24),

11. 7183297 - Biphenyl-derivatives as p38-kinase inhibitors (2007-02-27),

12. 7166623 - 2'-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors (2007-01-23),

13. 7151118 - Biphenylcarboxylic amide derivatives as p38-kinase inhibitors (2006-12-19),

Title: Richard Angell: Innovator in Pharmaceutical Compounds

Introduction

Richard Angell is a notable inventor based in London, GB, with an impressive portfolio that includes 13 patents. His innovative work primarily focuses on the development of pharmaceutical compounds and their applications in medical treatments, particularly in the fight against various cancers.

Latest Patents

Angell's latest patents include groundbreaking inventions such as substituted naphthalene diimides, which are pivotal in the synthesis of compounds with DNA-quadruplex binding and stabilizing activities. These naphthalene diimides hold potential for treating pancreatic, prostate, and other human cancers. Additionally, his work on benzimidazole compounds outlines a formula that creates inhibitors of respiratory syncytial virus (RSV), showcasing his contributions to virology and therapeutic advancements.

Career Highlights

Throughout his career, Richard Angell has been associated with prominent companies, including Glaxo Group Limited and SmithKline Beecham Corporation. His experiences in these organizations have played a significant role in shaping his innovative thinking and have provided him with the platform to develop his impactful patents.

Collaborations

Angell has collaborated with several esteemed professionals in the field, including Paul Bamborough and Ann Louise Walker. These partnerships have enabled him to enhance his research and expand the reach of his innovations in the pharmaceutical industry.

Conclusion

Richard Angell's contributions to the field of pharmaceuticals through his innovative patents illustrate his commitment to advancing medical science. His work in developing compounds for cancer treatment and viral infections stands as a testament to his ingenuity and dedication to enhancing healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.